- Home
- ACVA vs AVDL Comparison
ACVA vs AVDL Comparison
Compare ACVA & AVDL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACVA
- AVDL
- Stock Information
- Founded
- ACVA 2014
- AVDL 2015
- Country
- ACVA United States
- AVDL Ireland
- Employees
- ACVA N/A
- AVDL N/A
- Industry
- ACVA Business Services
- AVDL Biotechnology: Pharmaceutical Preparations
- Sector
- ACVA Consumer Discretionary
- AVDL Health Care
- Exchange
- ACVA Nasdaq
- AVDL Nasdaq
- Market Cap
- ACVA 1.6B
- AVDL 1.8B
- IPO Year
- ACVA 2021
- AVDL 1996
- Fundamental
- Price
- ACVA $6.81
- AVDL $23.07
- Analyst Decision
- ACVA Buy
- AVDL Buy
- Analyst Count
- ACVA 14
- AVDL 9
- Target Price
- ACVA $14.35
- AVDL $18.38
- AVG Volume (30 Days)
- ACVA 6.7M
- AVDL 2.7M
- Earning Date
- ACVA 11-05-2025
- AVDL 11-04-2025
- Dividend Yield
- ACVA N/A
- AVDL N/A
- EPS Growth
- ACVA N/A
- AVDL N/A
- EPS
- ACVA N/A
- AVDL N/A
- Revenue
- ACVA $735,475,000.00
- AVDL $248,517,000.00
- Revenue This Year
- ACVA $22.90
- AVDL $64.21
- Revenue Next Year
- ACVA $19.07
- AVDL $30.80
- P/E Ratio
- ACVA N/A
- AVDL N/A
- Revenue Growth
- ACVA 23.40
- AVDL 79.88
- 52 Week Low
- ACVA $4.95
- AVDL $6.38
- 52 Week High
- ACVA $23.46
- AVDL $23.57
- Technical
- Relative Strength Index (RSI)
- ACVA 41.71
- AVDL 82.66
- Support Level
- ACVA $5.34
- AVDL $18.74
- Resistance Level
- ACVA $6.65
- AVDL $23.28
- Average True Range (ATR)
- ACVA 0.49
- AVDL 0.29
- MACD
- ACVA 0.10
- AVDL 0.28
- Stochastic Oscillator
- ACVA 41.90
- AVDL 89.64
About ACVA ACV Auctions Inc.
ACV Auctions Inc is a mobile platform for wholesale car auctions. The company provides a digital marketplace for wholesale vehicle transactions and data services that offer transparent and accurate vehicle information for customers.
About AVDL Avadel Pharmaceuticals plc
Avadel Pharmaceuticals PLC is a specialty pharmaceutical company. The group focused on transforming medicines to transform lives. It provides solutions to the development of medications that address the challenges patients face with current treatment options. The company is engaged in the development of differentiated drug products for administration in various forms such as capsules, tablets, injectables etc. Its commercialized product LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in adults with narcolepsy. It operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology.